What is Co-Dx?
Co-Diagnostics, Inc., operating as Co-Dx, is a Salt Lake City, Utah-based entity specializing in the development, manufacturing, and sale of reagents for diagnostic tests. The company's core technology revolves around its Co-Dx PCR platform, which enables the detection and analysis of nucleic acid molecules. This platform is utilized for a wide array of diagnostic tests, including those for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. Co-Dx also extends its molecular diagnostic capabilities to point-of-care and at-home settings, offering multiplexed tests for mosquito-borne diseases, tools for infectious disease detection, liquid biopsy for cancer screening, and agricultural applications for identifying genetic traits in plant and animal genomes. The company's commitment to innovation is further demonstrated by its portable diagnostic device, designed to bring advanced PCR testing directly to patients.
How much funding has Co-Dx raised?
Co-Dx has raised a total of $13.1M across 3 funding rounds:
Debt
$750K
Stock Offering
$7.1M
Grant
$2.3M
Debt (2016): $750K, investors not publicly disclosed
Stock Issuance/Offering (2017): $7.1M, investors not publicly disclosed
Grant (2023): $2.3M supported by Bill & Melinda Gates Foundation
Key Investors in Co-Dx
Bill & Melinda Gates Foundation
Established in 2000 and headquartered in Seattle, Washington, The Bill & Melinda Gates Foundation is an organization that focuses on supporting individuals experiencing hunger and extreme poverty in leading healthier lives. Their investment in Co-Dx highlights a commitment to advancing global health through innovative diagnostic solutions.
What's next for Co-Dx?
The recent major strategic investment and significant grant signal a period of accelerated growth and development for Co-Dx. This influx of capital is likely to fuel further research and development into new diagnostic assays and expand the company's market reach, particularly in point-of-care and at-home testing solutions. The company's focus on multiplexed testing and portable devices positions it to address critical public health needs and capitalize on emerging opportunities in personalized medicine and infectious disease surveillance. Strategic partnerships and continued innovation will be key to leveraging this recent financing for sustained expansion and market leadership in the molecular diagnostics industry.
See full Co-Dx company page
